LifeSplice Pharma is seeking an electrophysiologist with expertise in brain slice patch clamp recordings, to begin as soon as August 1st. Both post-doctoral applicants and experienced technicians are encouraged to apply. Salary to be based on experience and education; health care and other benefits are provided.
Candidate must understand the tenants of electrophysiological recording and have the experience to assemble a patch clamp rig and independently troubleshoot experiments. Additional experience in recording from cultured cells, extracellular recording in brain slices, and/or familiarity with mouse epilepsy models would be helpful.
The applicants will work closely with a small but dynamic group of scientists on pre-clinical stage projects to characterize the efficacy of novel oligonucleotide drug candidates developed by our company as therapeutics for treating epilepsy. A strong work ethic, reliability, resourcefulness, strong documentation and organizational skills, and ability to work both with a team and independently are all very important.
Candidates are encouraged to apply as soon as possible, as interviews will be conducted in the order in which applications are received. Candidates must be eligible to work in the US.
Please apply via "apply now" button on right side of this page. Submit a CV and address a short cover letter expressing your interest in the position, including when you would be available to start, to:
Melanie Tallent, PhD
Chief Scientific Officer
Resume submissions from third party recruitment firms will not be considered.
At least one year of recent experience in brain slice electrophysiology is required. Candidates must be eligible to work in the United States and be willing to undergo a background check. A PhD is preferred but candidates with a bachelor's degree with a strong background in electrophysiology would also be considered.
Internal Number: 20190627
About LifeSplice Pharma
We are a small biotech company located west of Philadelphia. We develop proprietary oligonucleotide-based drugs that modify alternative splicing to treat severe neurological disorders.